# BGB-11417-101 (NCT04277637)

> Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04277637
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: BeOne Medicines
- Conditions: Mature B-Cell Malignancies
- Interventions: Sonrotoclax; Zanubrutinib; Obinutuzumab
- Enrollment: 437
- Primary outcome: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)
- Primary outcome: Number of Participants Experiencing Serious Adverse Events (SAEs)
- Primary outcome: Number of Participants Experiencing Adverse Events (AEs) leading to discontinuation of Sonrotoclax
- Primary outcome: Part 1, Part 3: Maximum Tolerated Dose (MTD) of Sonrotoclax
- Primary outcome: Part 1, Part 3, Part 5: RP2D of Sonrotoclax
- Primary outcome: Part 1, Part 3, Part 5: Number of participants experiencing tumor lysis syndrome (TLS) relevant events
- Primary outcome: Part 1, Part 3, Part 5: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs

## Indexed commentary on BGB-11417-101 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 4
- X threads: 3
- Podcasts: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=bgb-11417-101-nct04277637

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04277637", "email": "<work email>"}; the inbox owner confirms by the emailed link.